Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

There is no question that loss of cell cycle checkpoint regulation is an intrinsic characteristic of cancer. However, many tumors retain parallel checkpoint pathways that are activated by antitumor agents and facilitate therapeutic response. Failures in these therapy-linked checkpoint controls are closely associated with cancers that are highly resistant to therapeutic interventions. Checkpoint Controls and Targets in Cancer provides present-day mechanistic understandings of how multiple sets of proteins orchestrate cell cycle progression, discusses critical checkpoint controls that are evaded for cancer development, focuses on checkpoint pathways associated with antitumor effects, and identifies specific checkpoint regulators for targeting with small molecules in the clinical management of cancer. These aspects of cell cycle checkpoints are articulated critically by renowned experts from both academia and industry, and new concepts are forwarded that challenge existing dogmas. Collectively, Checkpoint Controls and Targets in Cancer provides a unique collection of insightful contributions, which are timely and offer significant interest and appeal to basic, translational and clinical scientists.

Antineoplastic agents -- Development. --- Cancer cells -- Growth -- Regulation. --- Cellular control mechanisms. --- Drug Resistance, Neoplasm --- Cell Cycle --- Pharmacology --- Cell Cycle Proteins --- Antineoplastic Agents --- Neoplasms --- Drug Therapy --- Proteins --- Biological Science Disciplines --- Therapeutics --- Cell Physiological Processes --- Diseases --- Therapeutic Uses --- Drug Resistance --- Amino Acids, Peptides, and Proteins --- Pharmacologic Actions --- Pharmacological Phenomena --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Natural Science Disciplines --- Cell Physiological Phenomena --- Physiological Phenomena --- Chemicals and Drugs --- Disciplines and Occupations --- Phenomena and Processes --- Chemical Actions and Uses --- Oncology --- Public Health - General --- Animal Biochemistry --- Human Anatomy & Physiology --- Public Health --- Medicine --- Health & Biological Sciences --- Antineoplastic agents --- Cancer cells --- Development. --- Growth --- Regulation. --- Cell regulation --- Regulation of cancer cell growth --- Medicine. --- Cancer research. --- Pharmacology. --- Oncology. --- Biomedicine. --- Cancer Research. --- Pharmacology/Toxicology. --- Tumors --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemicals --- Chemotherapy --- Drugs --- Pharmacy --- Cancer research --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Pathology --- Physicians --- Physiological effect --- Biological control systems --- Cell metabolism --- Cellular control mechanisms

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pharmacology. Therapy --- Oncology. Neoplasms --- farmacie --- farmacologie --- toxicologie --- oncologie

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

An estimated 1.5 million patients in the United States are diagnosed with cancer every year and over half-a-million individuals die of the disease. Since the vast majority of the deaths occur after medical intervention with anticancer therapy, both conventional chemotherapy and novel targeted therapy, it can be concluded that these patients die from drug resistant cancers. A growing number of studies have revealed that mechanisms underlying the development of drug resistance in cancer cells are manifold and complex and very likely are dependent on cell and microenvironment context. In view of these facts, it is important to document the mechanisms of drug resistance and understand which are the dominant resistance pathways in a particular tumor type that could provide potential therapeutic targets in a clinical setting. This book serves as a single source for the current knowledge on genetic and epigenetic alterations that contribute to the development of drug resistance. Comprehensive reviews written by renowned experts provide great insight on the current knowledge on drug resistance mechanisms. This book is a ready source of information to clinicians, cell and cancer biologists and defines molecular drug resistance mechanisms that are challenging scientists and clinical oncologists today. About Editors: Dr. Kapil Mehta is a Professor in the Department of Experimental Therapeutics, The University of Texas M. D Anderson Cancer Center, Houston, TX. He has published widely and received several patents on novel discoveries relating to drug resistance in the field of cancer therapeutics. Dr. Zahid H. Siddik is also a Professor in the Department of Experimental Therapeutics at The University of Texas M.D. Anderson Cancer Center. He has studied extensively the mechanisms of drug action and resistance, and is recognized for his seminal studies with platinum-based antitumor agents.